{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:22Z","timestamp":1740106942452,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004528","name":"Maastricht University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004528","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a haploidentical stem cell transplantation (haploSCT) can reduce the risk of myeloma relapse, we performed a small prospective phase 2 study in which we transplanted poor-risk MM patients using a killer cell immunoglobulin-like receptor (KIR)-ligand mismatched haploidentical donor. Patients received bone marrow grafts after reduced-intensity conditioning, with post-transplantation cyclophosphamide (PTCY) graft-versus-host-disease (GVHD) prophylaxis. The primary endpoint was 1.5-year progression-free survival (PFS); stopping rules were installed in case interim results made a benefit of 50% PFS at 1.5 years unlikely. After inclusion of 12 patients, of which 9 were evaluable for the primary endpoint, all patients relapsed within a median time of 90 days. All except 1 patient showed engraftment, with a median time to neutrophil recovery of 18 (12\u201330) days. The study was prematurely terminated based on the predefined stopping rules after the inclusion of 12 patients. With this small study, we show that in chemo-resistant myeloma patients, NK cell KIR-mismatch is not superior to conventional alloSCT. This strategy, however, can serve as a platform for new treatment concepts.<\/jats:p><jats:p>Clinical Trial Registry: NCT02519114<\/jats:p>","DOI":"10.1007\/s00277-020-04303-z","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T08:02:32Z","timestamp":1603872152000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors"],"prefix":"10.1007","volume":"100","author":[{"given":"Catharina","family":"Van Elssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7834","authenticated-orcid":false,"given":"Gwendolyn","family":"van Gorkom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Voorter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"Wieten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"6","key":"4303_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bola\u00f1os-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641\u2013650","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"4303_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","volume":"102","author":"SR McCurdy","year":"2017","unstructured":"McCurdy SR, Kasamon YL, Kanakry CG, Bolanos-Meade J, Tsai HL, Showel MM et al (2017) Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 102(2):391\u2013400","journal-title":"Haematologica."},{"issue":"2","key":"4303_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbmt.2018.09.018","volume":"25","author":"F Sahebi","year":"2019","unstructured":"Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, R\u00f6sler W, Diez-Martin JL, Schoenland S, D'Souza A, Kr\u00f6ger N, Hari P (2019) Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT\/CIBMTR report. Biol Blood Marrow Transplant 25(2):335\u2013342","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"4303_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","volume":"23","author":"L Castagna","year":"2017","unstructured":"Castagna L, Mussetti A, Devillier R, Dominietto A, Marcatti M, Milone G, Maura F, de Philippis C, Bruno B, Furst S, Blaise D, Corradini P, Montefusco V (2017) Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 23(9):1549\u20131554","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4303_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41409-017-0069-1","volume":"53","author":"Y Chen","year":"2018","unstructured":"Chen Y, Lu J, Xu LP, Chen H, Zhang XH, Wang FR, Chen YH, Wang Y, Liu KY, Huang XJ (2018) Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplant 53(4):507\u2013510","journal-title":"Bone Marrow Transplant"},{"issue":"5562","key":"4303_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (New York, NY) 295(5562):2097\u20132100","journal-title":"Science (New York, NY)"},{"issue":"13","key":"4303_CR7","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","volume":"113","author":"D Pende","year":"2009","unstructured":"Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A (2009) Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 113(13):3119\u20133129","journal-title":"Blood."},{"issue":"3","key":"4303_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","volume":"102","author":"S Giebel","year":"2003","unstructured":"Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 102(3):814\u2013819","journal-title":"Blood."},{"issue":"3","key":"4303_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","volume":"24","author":"A Wanquet","year":"2018","unstructured":"Wanquet A, Bramanti S, Harbi S, Furst S, Legrand F, Faucher C et al (2018) Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide. Biol Blood Marrow Transplant 24(3):549\u2013554","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"4303_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ejh.12616","volume":"96","author":"M Bastos-Oreiro","year":"2016","unstructured":"Bastos-Oreiro M, Anguita J, Martinez-Laperche C, Fernandez L, Buces E, Navarro A et al (2016) Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation. Eur J Haematol 96(5):483\u2013491","journal-title":"Eur J Haematol"},{"issue":"7","key":"4303_CR11","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.4049\/jimmunol.1801489","volume":"202","author":"C Willem","year":"2019","unstructured":"Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, Peterlin P, Garnier A, B\u00e9n\u00e9 MC, Cesbron A, le Bourgeois A, Chevallier P, Reti\u00e8re C (2019) Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide. J Immunol 202(7):2141\u20132152","journal-title":"J Immunol"},{"issue":"2","key":"4303_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","volume":"131","author":"A Russo","year":"2018","unstructured":"Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, Toffalori C, Zito L, Lorentino F, Piemontese S, Morelli M, Giglio F, Assanelli A, Stanghellini MTL, Bonini C, Peccatori J, Ciceri F, Luznik L, Vago L (2018) NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 131(2):247\u2013262","journal-title":"Blood."},{"issue":"13","key":"4303_CR13","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1182\/blood-2005-04-1644","volume":"106","author":"S Cooley","year":"2005","unstructured":"Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS (2005) KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 106(13):4370\u20134376","journal-title":"Blood."},{"issue":"3","key":"4303_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1600-0609.1990.tb00443.x","volume":"45","author":"A Osterborg","year":"1990","unstructured":"Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H (1990) Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 45(3):153\u2013157","journal-title":"Eur J Haematol"},{"issue":"3","key":"4303_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","volume":"119","author":"C Frohn","year":"2002","unstructured":"Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J (2002) Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 119(3):660\u2013664","journal-title":"Br J Haematol"},{"issue":"18","key":"4303_CR16","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","volume":"67","author":"YM El-Sherbiny","year":"2007","unstructured":"El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW et al (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67(18):8444\u20138449","journal-title":"Cancer Res"},{"issue":"1","key":"4303_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","volume":"105","author":"E Carbone","year":"2005","unstructured":"Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 105(1):251\u2013258","journal-title":"Blood."},{"key":"4303_CR18","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","volume":"9","author":"KS Campbell","year":"2018","unstructured":"Campbell KS, Cohen AD, Pazina T (2018) Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma. Front Immunol 9:2551","journal-title":"Front Immunol"},{"issue":"14","key":"4303_CR19","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","volume":"8","author":"M Giuliani","year":"2017","unstructured":"Giuliani M, Janji B, Berchem G (2017) Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 8(14):24031\u201324044","journal-title":"Oncotarget."},{"issue":"5","key":"4303_CR20","doi-asserted-by":"publisher","first-page":"e64835","DOI":"10.1371\/journal.pone.0064835","volume":"8","author":"S Sarkar","year":"2013","unstructured":"Sarkar S, Germeraad WT, Rouschop KM, Steeghs EM, van Gelder M, Bos GM et al (2013) Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One 8(5):e64835","journal-title":"PLoS One"},{"key":"4303_CR21","first-page":"008","volume":"2","author":"S Sarkar","year":"2015","unstructured":"Sarkar S, Noort W, van Elssen C, Groen R, van Bloois L, van Gelder M, Schouten H, Tilanus M, Germeraad W, Wieten L, Martens A, Bos G (2015) Alloreactive Natural Killer cells have anti-tumor capacity against disseminated human multiple myeloma in Rag2-\/-\u03b3C-\/-mice when combined with low dose cyclophosphamide and total body irradiation. HSAO J Clin Immunol Immunother 2:008","journal-title":"HSAO J Clin Immunol Immunother"},{"issue":"5","key":"4303_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, DuPont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy Jr JD, Barlogie B, van Rhee F (2008) Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 143(5):641\u2013653","journal-title":"Br J Haematol"},{"issue":"5","key":"4303_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","volume":"129","author":"N Kroger","year":"2005","unstructured":"Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhauser M, Ayuk F, Zander AR, Marks DI, the Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group (2005) Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129(5):631\u2013643","journal-title":"Br J Haematol"},{"issue":"8","key":"4303_CR24","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013ee46","journal-title":"Lancet Oncol"},{"key":"4303_CR25","doi-asserted-by":"crossref","unstructured":"Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y et al (2020) Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia 34:2766\u20132775","DOI":"10.1038\/s41375-020-0850-9"},{"issue":"7","key":"4303_CR26","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cncr.31228","volume":"124","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Gulbas Z, Koc Y, Blaise D et al (2018) Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 124(7):1428\u20131437","journal-title":"Cancer."},{"issue":"16","key":"4303_CR27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE (2017) Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 130(16):1857\u20131868","journal-title":"Blood."},{"issue":"1","key":"4303_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, Andre P, Horowitz A, Ruan DF, Borst L, Zerbib R et al (2019) Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer 7(1):263","journal-title":"J Immunother Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04303-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T10:33:42Z","timestamp":1609756422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04303-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4303"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04303-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G. Bos is C.E.O. CiMaas bv, Maastricht, The Netherlands. All other authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}